HOME >> BIOLOGY >> NEWS
NIH announces phase III clinical trial of creatine for Parkinson's disease

The NIH National Institute of Neurological Disorders and Stroke (NINDS) today is launching a large-scale clinical trial to learn if the nutritional supplement creatine can slow the progression of Parkinson's disease (PD). While creatine is not an approved therapy for PD or any other condition, it is widely thought to improve exercise performance. The potential benefit of creatine for PD was identified by Parkinsons researchers through a new rapid method for screening potential compounds.

The double-blind, placebo-controlled, phase III study is one of the largest PD clinical trials to date. It will enroll 1720 people with early-stage PD at 51 medical centers in the United States and Canada.

"This study is an important step toward developing a therapy that could change the course of this devastating disease," says Elias A. Zerhouni, M.D., director of the NIH. "The goal is to improve the quality of life for people with Parkinson's for a longer period of time than is possible with existing therapies." Currently there is no treatment that has been shown to slow the progression of PD.

The trial is the first large study in a series of NINDS-sponsored clinical trials called NET-PD (NIH Exploratory Trials in Parkinson's Disease). NINDS has organized this large network of sites to allow researchers to work with PD patients over a long period of time, with a goal of finding effective and lasting treatments. NET-PD builds on a developmental research processfrom laboratory research to pilot studies in a select group of patients, to the definitive phase III trial of effectiveness in people with Parkinsons disease.

"This study is an example of the Institute's commitment to Parkinson's research," says NINDS director Story C. Landis, Ph.D. "We are trying to explore every possible option for reducing the burden of this disease."

Participants will be in the phase III study for five to seven years. The effort will be led by
'"/>

Contact: Margo Warren
warrenm@ninds.nih.gov
301-496-5924
NIH/National Institute of Neurological Disorders and Stroke
22-Mar-2007


Page: 1 2 3

Related biology news :

1. Almac Diagnostics announces pioneering genetic research on ductal carcinoma in situ
2. ESA announces 2007 award recipients
3. President Bush announces 2005 and 2006 Laureates of National Medals of Science and Technology
4. Conservation Leadership Program announces 2007 awardees
5. ACMG Foundation announces 2007-2008 Luminex/ACMGF award recipient
6. Revolutionary global environment fund announces $50M expansion
7. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
8. Cell Press announces new partnership with the American Society of Human Genetics
9. ChemGenex announces publication confirming activity of Ceflatonin in T315I-Positive CML
10. Minister Lunn announces $39.6M for next phase of mountain pine beetle response
11. BioMed Central announces new interdisciplinary Biofuels Journal

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/3/2019)... ... October 02, 2019 , ... Personalized Stem Cells, ... patient in an FDA approved clinical trial for stem cell treatment of knee ... formation of the company as a subsidiary of VetStem Biopharma. , PSC CEO, Michael ...
(Date:9/30/2019)... ... September 30, 2019 , ... ... mesenchymal stem/stromal cell (hMSC) biomanufacturing systems, today announced it has received patent ... product formats (patent number AU 2015259373). This new patent adds intellectual property ...
(Date:9/25/2019)... ... , ... Deep Science Ventures (DSV), a new paradigm for applied ... of cancer research. , Deep Science Ventures was founded to create a better method ... from the start, both at the industry and biological level. , Through their ...
Breaking Biology News(10 mins):
(Date:9/30/2019)... (PRWEB) , ... September 30, 2019 , ... ... materials science newsletter from Rigaku Corporation , is now available online on ... to X-ray based materials science, including X-ray diffraction, fluorescence and imaging, and presents ...
(Date:9/24/2019)... (PRWEB) , ... September 24, ... ... provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, ... a clinical-stage biopharmaceutical company focused on the development of therapies to treat ...
(Date:9/24/2019)... ... , ... In the past three years, the National Science Foundation (NSF) has ... School of Mines & Technology that expands human understanding of the microbial world. ... slimy and yet strong layer which is commonly known as a biofilm. , The ...
(Date:9/17/2019)... ... 2019 , ... Tucker, a Labrador retriever, was just a puppy when he ... and lame on his right hip and elbow. At one year of age, Tucker ... case the vet had seen.” He was prescribed pain medications, both oral and injectable, ...
Breaking Biology Technology:
Cached News: